Zie ook in gerelateerde artikelen

20 april 2026: Bron: persbericht van Memorial Sloan Kettering Cancer Center d.d. 18 april 2026 en AACR 2026

Immuuntherapie met Herceptin - Trastuzumab plus Tucatinib - Tukysa gericht op een aangetoonde positieve HER2neu expressie en met een aantoonbare KRAS mutatie gevolgd door chemotherapie met of met Capecitabine/Xeloda of Oxaliplatin/FOLFOX voorkomt een patiëntbelastende operatie bij nog niet eerder behandelde patiënten met endeldarmkanker. Aldus de tussenresultaten van een fase II studie.

De twee geneesmiddelen Herceptin - Trastuzumab plus Tucatinib - Tukysa werden de eerste zes weken afzonderlijk toegediend, en daarna in combinatie met standaardchemotherapie. Voor al deze deelnemende kankerpatiënten met rectumkanker was een grote operatie voorzien en gepland. Maar al tijdens de studie zagen 4 van de 8 patiënten hun tumoren verdwijnen met alleen de Herceptin - Trastuzumab plus Tucatinib - Tukysa en chemotherapie.
Bij drie patiënten begonnen de tumoren al snel opnieuw te groeien, maar deze werden daarna zonder operatie succesvol behandeld met bestraling of een minimaal invasieve operatieve ingreep.

"Bestraling en chirurgie zijn meestal succesvol bij endeldarmkanker, maar ze hebben bijwerkingen die soms een grote impact op iemands leven kunnen hebben", legt gastro-intestinale oncoloog Andrea Cercek, MD, uit, die het onderzoek leidde.
Deze bijwerkingen kunnen onder andere bestaan ​​uit een verminderde seksuele functie en vruchtbaarheid, evenals de noodzaak van een tijdelijke of permanente stoma, een extern zakje voor het opvangen van ontlasting.
"Ons doel was om de toxiciteit van de behandelingen te minimaliseren", legt dr. Cercek uit. "Als we met deze nieuwe aanpak mensen bijvoorbeeld een permanente stoma kunnen besparen, is dat een grote winst voor de patiënten."

Op de AACR 2026 werden deze tussenresultaten gepubliceerd van 8 patiënten met nog niet eerder behandelde rectumkanker. Hier het persbericht van het Memorial Sloan Kettering Cancer Center. Daaronder een overzicht van studies naar behandelingen van patiënten met endeldarmkanker met HER2neu expressie.

Treating HER2-Amplified Early-Stage Rectal Cancer To Improve Quality of Life

By Bill PiersolSaturday, April 18, 2026

A clinical trial at Memorial Sloan Kettering Cancer Center (MSK) is showing promise for people with early-stage rectal cancer whose tumors are driven by excessive amounts of a protein called HER2 (human epidermal growth factor receptor 2).

The trial suggests that many of these patients may be successfully treated using targeted therapies to avoid surgery, resulting in fewer side effects and better quality of life during and after treatment. 

The phase 2 study treated eight people fully with early-stage rectal tumors using two well-known targeted therapies — trastuzumab (Herceptin) and tucatinib (Tukysa) — that attack HER2-driven tumors. The two drugs were given alone for the first six weeks, then afterwards in combination with standard chemotherapy. 

Typically, these rectal cancer patients would eventually undergo a large surgery. But in the trial, 4 of the 8 patients saw their tumors disappear using only the targeted therapies and chemotherapy. In three patients, tumors began to regrow but were managed without surgery, using radiation or a minimally-invasive procedure.

Overall, the targeted therapies were well tolerated, with side effects that were manageable. >>>>>>>>reed more


Hieronder de literatuurstudie:

Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review

https://doi.org/10.1016/j.ctrv.2026.103097Get rights and content
Under a Creative Commons license
Open access

Highlights

  • •
    Clinical trials show the utility of HER2-targeted treatments for HER2 + mCRC.
  • •
    Strong evidence emerged from the MOUNTAINEER and DESTINY-CRC01 trials.
  • •
    Regulatory criteria for determining HER2 overexpression in mCRC are needed.
  • •
    Patients with mCRC are not routinely assessed for HER2 overexpression.
  • •
    Early testing for HER2 overexpression would aid access to HER2-targeted treatments.

Abstract

Human epidermal growth factor receptor 2 (HER2)-targeted therapies have been investigated for therapeutic benefit in RAS/BRAF wild-type/HER2+ metastatic colorectal cancer (mCRC). Unlike HER2+ breast and gastric cancer, there are no regulatory criteria for determining HER2 overexpression in patients with mCRC. This systematic literature review describes unmet needs for patients with HER2+ mCRC in relation to testing and treatment, highlights the importance of early HER2 testing at mCRC diagnosis, and discusses the evolving treatment landscape. We utilised PubMed and EMBASE databases up to November 2023 to identify journal articles and published congress abstracts relating to the HER2+ disease and treatment landscape, HER2 testing in mCRC, and HER2-targeted treatments in mCRC. Many studies have demonstrated the utility of immunohistochemistry, in situ hybridisation, and next-generation sequencing (tissue- and circulating tumour DNA-based) for detecting HER2 overexpression/amplification in mCRC and have attempted to establish consolidated criteria like those used for breast and gastric cancer. The value of HER2-targeted treatments in patients with HER2+ mCRC has been evidenced by clinical trials and meta-analyses, with strong evidence from MOUNTAINEER and DESTINY-CRC01 which supports the use of tucatinib + trastuzumab or trastuzumab deruxtecan, respectively, among this patient population. However, real-world analyses have confirmed that patients with HER2+ mCRC are not routinely tested for HER2 overexpression. Strong evidence and clinical guidelines support the value of HER2-targeted treatment among patients with HER2+ mCRC. There is a need for increased awareness and earlier uptake of HER2 testing among patients with mCRC to broaden treatment options and optimise outcomes for this patient population.
 

Outline

  1. Highlights
  2. Abstract
  3. Keywords
  4. Introduction
  5. Methods
  6. Results
  7. Conclusions
  8. Funding
  9. Declaration of competing interest
  10. Acknowledgements
  11. Appendix A. Supplementary data
  12. References

Funding

This systematic literature review was sponsored by Seagen Inc., which was acquired by Pfizer in December 2023.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Salvatore Siena: Reports advisory board membership roles for Agenus, AstraZeneca, Bayer, BMS, CheckmAb, Daiichi Sankyo, GSK, MSD, Merck, Novartis, Pierre-Fabre, Seagen, and T-One Therapeutics. Myriam Chalabi: Reports advisory roles for NUMAB, KINETA, BMS, MSD, and Roche/Genentech; and research grants not related to this paper by BMS, MSD, and Roche-Genentech. All grants were paid to the institution. Rachel Goodwin: Reports advisory board membership roles for AAA/Novartis, Ipsen, Pfizer, Amgen, Roche, Merck, AstraZeneca, Taiho, Apobiologix, Eisai, BMS, and Astellas; speaker roles for AAA, Ipsen, Pfizer, Amgen, Merck, AstraZeneca, Eisai, BMS, and Astellas; a travel grant from Ipsen; independent education grants from Apobiologix, Ipsen, and Pfizer; and inclusion of patients in clinical trials. Pia Osterlund: Reports speaker/consultancy/advisory board honoraria, and/or research funding to institution, from Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, Eisai, Fresenius Kabi, Nordic Drugs/Pharma, Merck, MSD, Novartis, Nutricia, Pfizer, Pierre-Fabre, Roche, Sanofi, Scandion Oncology Servier, and Takeda. Frédérique Penault-Llorca: Reports speaker/consultancy honoraria from AstraZeneca, BeiGene, Daiichi Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Seagen, Sanofi, Medscape, Gilead, Lilly, Astellas, and Amgen; and travel grants from AstraZeneca, Roche, Pfizer, Daiichi Sankyo, Gilead, MSD, and Novartis. Andrea Sartore-Bianchi: Reports advisory board membership roles for Bayer, Pierre-Fabre, Servier, and Takeda. Naureen Starling: Reports research funding from AstraZeneca, BMS, Gilead, Guardant, Merck and Pfizer; travel and accommodation from AstraZeneca, BMS, GSK, Guardant, Merck, MSD Oncology, Roche, and Servier; honoraria from Amgen, BMS, Eli Lilly, GSK, Merck, MSD Oncology, Novartis, Pierre Fabre, Seagen, Servier; and advisory roles for AstraZeneca, BMS, Gilead, GSK, Guardant, Janssen, Moderna, MSD Oncology, Novartis, Pfizer, Seagen, Servier, and Takeda. Sebastian Stintzing: Reports personal fees for talks and advisory roles from Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, EISAI, Leo-Pharma, Lilly, Merck KGaA, MSD, Pierre-Fabre, Roche, Servier, Sysmex, Taiho, and Takeda; and institutional grants from Merck KGaA, Pierre-Fabre, Servier, and Roche. Josep Tabernero: Reports fees for advisory/consultancy roles with Alentis Therapeutics, AstraZeneca, Boehringer Ingelheim, Cardiff Oncology, CARSgen Therapeutics, Chugai, Daiichi-Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, hC Bioscience, Ikena Oncology, Immodulon Therapeutics, Inspirna Inc, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Takeda Oncology, and Tolremo Therapeutics; stocks from Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology, and 1TRIALSP; and educational collaboration with Medscape Education, PeerView Institute for Medical Education and Physicians Education Resource (PER)].

Acknowledgements

Medical writing support, including assisting authors with conducting the literature search and filtering, development of the outline and initial draft, and incorporation of comments was provided by Francesca Murphy, BA, CMPP, with support conducting the literature search and filtering from Patricia Badía Folgado, MA, and Sophie Byrne, MA, all of the Prime Group of Companies (Knutsford, UK). Editorial support, including referencing, figure preparation, formatting, proofreading, and submission was provided by Melissa Ward, BA, and Travis Taylor, BA, of the Prime Group of Companies (Knutsford, UK). Medical writing and editorial support were funded by Seagen according to Good Publication Practice guidelines (https://www.acpjournals.org/doi/full/10.7326/M22-1460?journalCode=aim). Seagen was involved in designing the literature search strategy and reviewed the final draft. However, ultimate responsibility for opinions, conclusions, and data interpretation lies with the authors. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Appendix A. Supplementary data

The following are the Supplementary data to this article:Supplementary Data 1

References

rectumkanker, Trastuzumab, Herceptin, Tucatinib, Tukysa, capecitabine, xeloda, oxaliplatin/FOLFOX, kwaliteit van leven, stoma, bijwerkingen, endeldarmkanker


Plaats een reactie ...

Reageer op "Trastuzumab plus Tucatinib gericht op HER2 expressie vooraf aan chemo voorkomt belastende operatie als eerstelijns behandeling bij patienten met onbehandelde rectumkanker met betere kwaliteit van leven omdat operatie niet meer nodig was"


Gerelateerde artikelen